Autor segons l'article: Papandreou, Christopher; Bullo, Monica; Hernandez-Alonso, Pablo; Ruiz-Canela, Miguel; Li, Jun; Guasch-Ferre, Marta; Toledo, Estefania; Clish, Clary; Corella, Dolores; Estruch, Ramon; Ros, Emilio; Fito, Montserrat; Alonso-Gomez, Angel; Fiol, Miquel; Santos-Lozano, Jose M; Serra-Majem, Lluis; Liang, Liming; Martinez-Gonzalez, Miguel A; Hu, Frank B; Salas-Salvado, Jordi
Departament: Bioquímica i Biotecnologia
Autor/s de la URV: Bulló Bonet, Mònica / Salas Salvadó, Jorge
Paraules clau: Trimethylamine-n-oxide Predimed Heart failure Choline metabolism Atrial fibrillation
Resum: © American Association for Clinical Chemistry 2020. All rights reserved. For permissions, please email: journals.permissions@oup.com. BACKGROUND: Few studies have examined the associations of trimethylamine-N-oxide (TMAO) and its precursors (choline, betaine, dimethylglycine, and L-carnitine) with the risk of atrial fibrillation (AF) and heart failure (HF). This study sought to investigate these associations. METHODS: Prospective associations of these metabolites with incident AF and HF were examined among participants at high cardiovascular risk in the PREDIMED study (PREvención con DIeta MEDiterránea) after follow-up for about 10 years. Two nested case-control studies were conducted, including 509 AF incident cases matched to 618 controls and 326 HF incident cases matched to 426 controls. Plasma levels of TMAO and its precursors were semi-quantitatively profiled with liquid chromatography tandem mass spectrometry. Odds ratios were estimated with multivariable conditional logistic regression models. RESULTS: After adjustment for classical risk factors and accounting for multiple testing, participants in the highest quartile vs. the lowest quartile of baseline choline and betaine levels had a higher risk of AF [OR (95% CI): 1.85 (1.30-2.63) and 1.57 (1.09-2.24), respectively]. The corresponding OR for AF for extreme quartiles of dimethylglycine was 1.39 (0.99-1.96). One SD increase in log-transformed dimethylglycine was positively associated with AF risk (OR, 1.17; 1.03-1.33). The corresponding ORs for HF for extreme quartiles of choline, betaine, and dimethylglycine were 2.51 (1.57-4.03), 1.65 (1.00-2.71) and 1.65 (1.04-2.61), respectively. TMAO and L-carnitine levels were not associated with AF or HF. CONCLUSIONS: Our findings support the role of the choline metabolic pathway in the pathogenesis of AF and HF.
Àrees temàtiques: Odontología Medicine (miscellaneous) Medicine (all) Medicina iii Medicina ii Medicina i Medical laboratory technology General medicine Farmacia Clinical biochemistry Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Biotecnología Biochemistry (medical)
Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
Adreça de correu electrònic de l'autor: monica.bullo@urv.cat jordi.salas@urv.cat
Identificador de l'autor: 0000-0002-0218-7046 0000-0003-2700-7459
Data d'alta del registre: 2024-10-12
Versió de l'article dipositat: info:eu-repo/semantics/submittedVersion
URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
Referència a l'article segons font original: Clinical Chemistry. 67 (1): 288-297
Referència de l'ítem segons les normes APA: Papandreou, Christopher; Bullo, Monica; Hernandez-Alonso, Pablo; Ruiz-Canela, Miguel; Li, Jun; Guasch-Ferre, Marta; Toledo, Estefania; Clish, Clary; C (2021). Choline Metabolism and Risk of Atrial Fibrillation and Heart Failure in the PREDIMED Study. Clinical Chemistry, 67(1), 288-297. DOI: 10.1093/clinchem/hvaa224
Entitat: Universitat Rovira i Virgili
Any de publicació de la revista: 2021
Tipus de publicació: Journal Publications
Repositori URV